Literature DB >> 28505219

64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.

S Sasada1, H Kurihara2, T Kinoshita3, M Yoshida4, N Honda2, T Shimoi1, A Shimomura1, M Yunokawa1, K Yonemori1, C Shimizu1, A Hamada5, Y Kanayama6, Y Watanabe6, Y Fujiwara1, K Tamura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28505219     DOI： 10.1093/annonc/mdx227

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.

Authors:  Shinsuke Sasada; Hiroaki Kurihara; Takayuki Kinoshita; Masayuki Yoshida; Natsuki Honda; Tatsunori Shimoi; Akihiko Shimomura; Kan Yonemori; Chikako Shimizu; Akinobu Hamada; Yousuke Kanayama; Yasuyoshi Watanabe; Yasuhiro Fujiwara; Kenji Tamura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-03       Impact factor: 9.236

Review 2.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

Review 3.  Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer.

Authors:  Ziqi Li; Mariam S Aboian; Xiaohua Zhu; Bernadette Marquez-Nostra
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

Review 4.  The blood-tumour barrier in cancer biology and therapy.

Authors:  Patricia S Steeg
Journal:  Nat Rev Clin Oncol       Date:  2021-07-12       Impact factor: 66.675

Review 5.  64Cu-based Radiopharmaceuticals in Molecular Imaging.

Authors:  Yeye Zhou; Jihui Li; Xin Xu; Man Zhao; Bin Zhang; Shengming Deng; Yiwei Wu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer.

Authors:  Ilhan Lim; Woo Chul Noh; Inki Lee; Byung Hyun Byun; Byung Il Kim; Chang Woon Choi; Sang-Keun Woo; Kwang Il Kim; Kyo Chul Lee; Joo Hyun Kang; Min-Ki Seong; Hyun-Ah Kim; Sang Moo Lim
Journal:  EJNMMI Res       Date:  2021-01-21       Impact factor: 3.138

7.  The Prediction of HER2-Targeted Treatment Response Using 64Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report.

Authors:  Ilhan Lim; Woo Chul Noh; Inki Lee; Byung Hyun Byun; Byung Il Kim; Chang Woon Choi; Kyo Chul Lee; Choong Mo Kang; Min-Ki Seong; Hyun-Ah Kim; Sang Moo Lim
Journal:  J Breast Cancer       Date:  2022-01-21       Impact factor: 3.588
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.